Literature DB >> 3987181

Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.

S Vozeh, T Uematsu, T W Guentert, H R Ha, F Follath.   

Abstract

3-OH-quinidine, a major quinidine metabolite, has been reported to have antiarrhythmic activity in animals and is suspected to contribute to the effect of quinidine in man. Four healthy subjects received 3-OH-quinidine in increasing oral doses (35, 100, 300 mg) to achieve serum concentrations in the range of those after quinidine dosing in patients. Blood and urine were collected up to 48 hours and blood pressure, heart rate, and averaged ECG complexes were recorded during 12 hours after dosing. Kinetic analysis revealed differences from published data for the parent drug. Renal clearance was 16 L/hr. The elimination t1/2 was 12.4 hours, substantially longer than that of quinidine. No systematic ECG changes were observed in two subjects with maximum concentrations of 55 and 215 micrograms/L. In the other two subjects who achieved higher maximum concentrations (447 and 918 micrograms/L), there was a significant relationship between the length of the corrected QT interval and the serum concentration of 3-OH-quinidine. These first dynamic results indicate that 3-OH-quinidine exerts effects in man resembling those of quinidine and may contribute to the antiarrhythmic activity of quinidine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987181     DOI: 10.1038/clpt.1985.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Authors:  R A Wooding-Scott; J Smalley; J Visco; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 3.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

4.  Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.

Authors:  P Jaillon; J M Poirier; B Lecocq; C Jarreau; M Pays; M O Richard; G Cheymol
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

5.  Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

Authors:  K Brøsen; F Davidsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.